[Efalizumab. Long-term treatment of psoriasis].

Efalizumab is a humanized monoclonal CD11a-antibody. It inhibits T-cell migration and activation which are essential steps in the immunopathogenesis of psoriasis. Clinical studies have demonstrated that efalizumab is efficient and safe in the treatment of chronic plaque psoriasis. Approximately 30% of patients achieve an improvement in PASI of > or =75% within 12 weeks, with further clinical benefit noted with continued therapy. Efalizumab thus appears as an important option in the long-term management of chronic plaque psoriasis.
AuthorsJ C Prinz
JournalDer Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete (Hautarzt) Vol. 56 Issue 9 Pg. 812-8 (Sep 2005) ISSN: 0017-8470 [Print] Germany
Vernacular TitleEfalizumab. Dauertherapie der Psoriasis.
PMID16096737 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Dermatologic Agents
  • efalizumab
  • Antibodies, Monoclonal (administration & dosage)
  • Chronic Disease
  • Clinical Trials as Topic
  • Dermatologic Agents (administration & dosage)
  • Humans
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians'
  • Prognosis
  • Psoriasis (drug therapy, epidemiology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: